See Article by Porter et al
The ultrasound contrast agents that have been used in humans vary in terms of their composition, including the content of their gas core (perfluorocarbons, SF 6 ) although all are high-molecular weight gases with relatively low solubility and diffusivity to improve stability in vivo. 1 There are also differences in encapsulation strategy (albumin, lipid), although a common thread has been that the viscoelastic properties must be appropriate to allow nonlinear oscillation even during low mechanical index (MI) imaging. 1 Commercially produced agents also vary in terms of size and size dispersion. It is important that the vast majority of microbubbles be smaller than the dimensions of the microvessels through which they travel, and yet, very small (sub-micron) bubbles are less stable because of surface tension and contribute relatively little to signal enhancement.
In this issue of Circulation: Cardiovascular Imaging, Porter et al 2 report results from a collaborative study where signal enhancement during myocardial contrast echocardiography (MCE) was examined with a novel phase-shifting nanodroplet. This class of agents differ from microbubbles in that they are almost an order of magnitude smaller in diameter, have a predominately liquid-phase core, and require activation whereby diameter increases upon conversion of the core to gas phase (vaporization) during the pressure oscillations of the acoustic field. 3 By virtue of their size, these agents can potentially have extravascular access which may allow unique opportunities for contrast ultrasound imaging or for ultrasound-facilitated gene or drug delivery for disease states (cancer, inflammatory diseases) or tissues (liver, renal glomeruli) where microvascular permeability is enhanced. One could also imagine that site-targeted acoustic delivery of drug or gene could be further enhanced by phase conversion of nanodroplets directly upstream from the tissue of interest, particularly if the post-activated agent was sufficiently large to allow entrapment.
The study by Porter et al 2 is the first pre-clinical study to examine acoustic activation of nanodroplets within the ventricular cavity and subsequent myocardial enhancement. There are several important findings of this study. Although they did not perform a systematic evaluation of optimal conditions, the study is the first to show that conventional imaging parameters that are used in patients can convert nanodroplets to microbubbles in the left ventricular cavity and subsequently image the agent in the myocardial microcirculation. The authors have also provided important preliminary in vivo information on how ultrasound activation of the nanodroplets is dependent on acoustic pressure. On a practical note, the agent used in the study by Porter et al is relatively easy to prepare based on low-temperature condensation of gases that are already used in commercially produced agents. Finally, at least one of the agents that was tested was relatively easy to vaporize with ultrasound in the diagnostic range because of the relatively low boiling point of the octafluoropropane (C 3 F 8 ) when compared with similar compounds that have been used, such as dodecafluoropentane (C 5 F 12 ), which is generally liquid at room temperature, or with the condensed decafluorobutane (C 4 F 10 )-containing agent which Porter et al also tested.
An important contextual issue raised by the study by Porter et al is the question of "why". Is there much to be gained by using nanodroplets that have the added complexity of needing to be activated in vivo? In their justification, the authors are probably correct (at least for polydisperse contrast agents) that a large proportion of the agent is too labile to contribute to signal generation during the real-time low-power imaging methods that are now routinely used for MCE perfusion imaging. However, this is probably not a major drawback for commercially produced microbubble agents that have a much narrower size distribution, nor is there anything necessarily wrong with simply compensating with higher dose. Other theoretical potential advantages of nanodroplets must be considered. Based on the knowledge of size-dependent clearance of liposomes, one would predict that nanoscale agents would circulate longer than conventional 1-5 μm diameter microbubbles. 4 This feature could potentially improve the stability of the blood pool concentration to the point of achieving stable
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Phase-Shifting Ultrasound Contrast Agents concentration after a single bolus injection. Unfortunately, the loss of the ultrasound signal from nanodroplets in under 3 minutes in this study indicated that reticuloendothelial clearance was still rapid. A significant limitation in the current practice of MCE perfusion imaging is that high microbubble concentration within the left or right ventricle produces attenuation of farfield territories. The use of nanodroplet phase-conversion agents could be an advantage. Cavity attenuation could be minimized if the contrast agent is activated at high MI and then imaged in the myocardial microcirculation seconds later at a lower MI. Also, it is known that the relationship between microbubble signal generation (scattering crosssection) and attenuation (absorption and extinction crosssection) are variably related based on size. The ability to generate ideally sized microbubbles that need to be stable for only the brief time of transfer from left ventricle to myocardium may reduce far-field shadowing. 5, 6 Amelioration of attenuation is likely to be a topic addressed in the next phase of investigation, although some of the illustrations of MCE imaging in the Porter study hint at relatively low posterior wall shadowing.
As one would expect with such a revolutionary concept, the application of nanodroplets during MCE perfusion imaging begs many questions. The optimal acoustic conditions for activation, including frequency, acoustic pressure, pulse duration, are unclear as are the effects of multipulse versus singlepulse imaging (each of which were used in this study in the form of power modulation and harmonic imaging). Because the dose was quantified simply as a volume (20% solution), it is not possible to compare signal to that from microbubbles in equivalent dose (either based on particle number or perfluorocarbon mass).
One critical issue that remains unresolved is the size of the microbubbles that are formed during ventricular activation. Previous studies with these perfluorocarbon nanodroplets have found that acoustic pressure influences not only the amount but also the size of vaporized microbubbles in an inverse manner. 7 Hence, one could surmise that microbubble size will vary considerably between patients based on body morphometrics that influence damping of ultrasound and that are not replicated in an animal study. The safety concern raised by unpredictable microbubble diameter (which can range between 1 and 20 μm in in vitro studies) 7 is not entirely solved in this study. The similar rates of decline in intensity from blood pool and myocardium illustrated in Figure 5 by Porter et al was used to argue that microbubbles were freely circulating. An alternative explanation is that microbubbles that were entrapped based on size were being continuously destroyed by the repetitive high-MI imaging pulses that were used to vaporize and image the bubbles. Only by shifting the ultrasound beam to an unexposed region and not seeing an abrupt increase in signal or by a measuring signal after a pause in imaging could one exclude microbubble lodging which can occur with bubbles as small as 5 μm. 8 The investigators of this study have adeptly noted that standard quantitative perfusion imaging with MCE cannot be performed with nanodroplets. If a single long activation sequence is performed followed by low MI imaging, then the microbubble concentration of blood pool entering the myocardium will vary too much over the time needed for standard destruction-replenishment approaches. One can use high-MI intermittent imaging (triggered to ECG) to simultaneously activate agent and image the microcirculation. However, changes in blood pool concentration of vaporized bubbles will again be expected caused by the progressive prolongation of the pulsing interval. There is the possibility of activating nanodroplets in the cavity and then measuring the transfer kinetics through the myocardium using low MI imaging. Unfortunately, this mathematical model measures flow per unit volume rather than flow itself unless one has the means to separately measure compartment volume and input function. 9 An interesting finding of the study was that robust signal enhancement was achieved with continuous high-MI imaging, which is not possible with conventional microbubbles. Continuous imaging at MI 1.1 should destroy microbubbles, if not in the cavity then during their slow microvascular transit. The finding of signal enhancement with these stetting implies that vaporized compared with standard microbubbles are either more resistant to destruction, larger (and hence less destructible), more plentiful, or are formed within the microcirculation itself. Unfortunately, continuous highpower imaging provides information primarily on blood volume which is likely to be useful only for detecting severe perfusion defects or infarction. However, if vaporization is occurring to a large extent within the microcirculation, then a "washout" analysis of contrast disappearance may be an alternative for introducing the kinetic information needed to assess perfusion. 10 In summary, the study by Porter et al provides some intriguing and novel findings on a new approach to MCE microvascular imaging. The major questions that now must be addressed are (1) is the formation of microbubbles reproducible and safe and (2) does this complicated approach have any major clinical advantage to state-of-the-art techniques already in practice today?
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